Page 1 of Clinical Trials for Histone deacetylases HDAC inhibitors, 324 Total Matches
- 1CompletedSafety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid TumoursLast Updated: November 25, 2011Condition(s): Solid Tumor
- 2RecruitingLast Updated: May 18, 2012Condition(s): Cutaneous T-cell Lymphoma; Histone Deacetylase Inhibitor; Lymphoma; Oncology
- 3RecruitingLast Updated: April 8, 2012Condition(s): Gastric Cancer; Histone Deacetylase Inhibitor
- 4RecruitingLast Updated: February 16, 2012Condition(s): Advanced Hematologic Malignancies
- 5CompletedLast Updated: March 29, 2012Condition(s): Lymphoma
- 6Not yet recruitingLast Updated: March 1, 2012Condition(s): HDAC Activity
- 7TerminatedLast Updated: February 1, 2012Condition(s): Hodgkin's Lymphoma
- 8TerminatedLast Updated: February 1, 2012Condition(s): Chronic Lymphocytic Leukemia
- 9CompletedLast Updated: November 25, 2011Condition(s): Hematological Disease; Lymphoid Malignancies
- 10CompletedLast Updated: January 31, 2012Condition(s): Myeloproliferative Diseases
- 11RecruitingLast Updated: December 5, 2011Condition(s): Graft-Versus-Host Disease
- 12RecruitingLast Updated: February 22, 2012Condition(s): Chordoma
- 13CompletedLast Updated: January 31, 2012Condition(s): Hodgkin's Lymphoma
- 14RecruitingLast Updated: May 18, 2012Condition(s): Multiple Myeloma
- 15RecruitingLast Updated: May 14, 2012Condition(s): Hematopoietic/Lymphoid Cancer; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; B-cell Adult Acute Lymphoblastic Leukemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Primary Central Nervous System Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Multiple Myeloma; Splenic Marginal Zone Lymphoma; T-cell Adult Acute Lymphoblastic Leukemia; Waldenstrom Macroglobulinemia
- 16RecruitingLast Updated: April 18, 2012Condition(s): Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
- 17RecruitingLast Updated: March 23, 2012Condition(s): Leukemia
- 18Active, not recruitingLast Updated: September 12, 2011Condition(s): Advanced Solid Tumors
- 19RecruitingLast Updated: March 26, 2012Condition(s): Advanced Cancer
- 20TerminatedLast Updated: August 26, 2005Condition(s): Malignant Melanoma
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Histone+deacetylases+HDAC+inhibitors
